NextCure (NASDAQ:NXTC) Earns “Buy” Rating from Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of NextCure (NASDAQ:NXTC) in a research report report published on Friday, Benzinga reports. They currently have a $4.00 target price on the stock.

Separately, HC Wainwright restated a buy rating and issued a $8.00 price target on shares of NextCure in a research report on Friday.

NextCure Stock Performance

Shares of NASDAQ:NXTC traded up $0.12 during trading hours on Friday, hitting $1.65. 129,103 shares of the company’s stock traded hands, compared to its average volume of 231,066. The company’s fifty day simple moving average is $1.72 and its two-hundred day simple moving average is $1.40. NextCure has a 52 week low of $0.98 and a 52 week high of $2.57. The company has a market cap of $46.15 million, a price-to-earnings ratio of -0.75 and a beta of 0.54.

NextCure (NASDAQ:NXTC) last posted its quarterly earnings results on Thursday, March 21st. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.02. On average, analysts anticipate that NextCure will post -1.65 EPS for the current fiscal year.

Hedge Funds Weigh In On NextCure

A number of hedge funds have recently added to or reduced their stakes in NXTC. Marquette Asset Management LLC bought a new position in shares of NextCure during the 4th quarter valued at $66,000. Acuitas Investments LLC lifted its position in shares of NextCure by 30.0% in the fourth quarter. Acuitas Investments LLC now owns 372,799 shares of the company’s stock worth $425,000 after buying an additional 85,982 shares during the last quarter. Cable Car Capital LLC acquired a new stake in shares of NextCure in the fourth quarter worth about $702,000. Finally, Assenagon Asset Management S.A. bought a new stake in shares of NextCure during the 1st quarter worth about $952,000. Institutional investors and hedge funds own 42.65% of the company’s stock.

NextCure Company Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.